Mycophenolate Mofetil: payments to doctors
Payments that named Mycophenolate Mofetil as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $20K
- Providers
- 4
- Transactions
- 44
- Average per transaction
- $462
The per-transaction average — $462 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4 providers the average total is $5,083, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Amneal Pharmaceuticals LLC | $8,217 | 40.4% |
| Akorn, Inc. | $5,700 | 28.0% |
| Mylan Inc. | $3,083 | 15.2% |
| Hikma Pharmaceuticals USA | $2,720 | 13.4% |
| Sandoz | $477 | 2.3% |
| Mylan Specialty L.p. | $133 | 0.7% |